Approval Package for:

APPLICATION NUMBER:

210649Orig1s000

Trade Name: Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg

Generic or Proper Name: Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets

Sponsor: Macleods Pharmaceuticals Limited

Approval Date: March 15, 2019

Indication: As a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg.
## CONTENTS

<table>
<thead>
<tr>
<th>Reviews / Information Included in this NDA Review.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
</tr>
<tr>
<td>Other Action Letters</td>
</tr>
<tr>
<td>Labeling</td>
</tr>
<tr>
<td>REMS</td>
</tr>
<tr>
<td>Summary Review</td>
</tr>
<tr>
<td>Officer/Employee List</td>
</tr>
<tr>
<td>Office Director Memo</td>
</tr>
<tr>
<td>Cross Discipline Team Leader Review</td>
</tr>
<tr>
<td>Clinical Review(s)</td>
</tr>
<tr>
<td>Product Quality Review(s)</td>
</tr>
<tr>
<td>Non-Clinical Review(s)</td>
</tr>
<tr>
<td>Statistical Review(s)</td>
</tr>
<tr>
<td>Clinical Microbiology / Virology Review(s)</td>
</tr>
<tr>
<td>Clinical Pharmacology Review(s)</td>
</tr>
<tr>
<td>Other Reviews</td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:

210649Orig1s000

APPROVAL LETTER
Dear Mr. Gasperlin:

Please refer to your New Drug Application (NDA) dated and received September 14, 2017, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following drug product:

- Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg

We acknowledge receipt of your amendments dated March 15, 2018 and September 15, 2018, which constituted complete responses to our March 13, 2018 and September 12, 2018, action letters, respectively.

This new drug application provides for the use of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg.

This NDA was reviewed under the President’s Emergency Plan for AIDS Relief (PEPFAR).

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text, except with the revisions listed below. Based on the data provided, the current expiration dating period is 12 months for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg in the following packaging configuration when stored below 30°C (86°F): 1) HDPE bottles containing 30 or 90 tablets with desiccant (silica gel), induction seal, and child-resistant cap and 2) HDPE bottle of 180 tablets with desiccant (silica gel), induction seal, and non-child-resistant cap.

**Prescribing Information Revisions**

1. HIGHLIGHTS, Box Warning: Replace “discountinue” with “discontinue”
2. HIGHLIGHTS: Present all headings in the center of a horizontal line and ensure each horizontal line is extended over the entire width of the column.
3. HIGHLIGHTS: Deleted the double white space between each major heading. This requirement was already implemented in the enclosed agreed-upon labeling text as only a single space is needed.
4. Contents: Table of Contents (TOC): Delete “4.1 Hypersensitivity” from CONTRAINDICATIONS

Patient Information Revisions

5. The formatting including the Times New Roman font was reverted back to the original formatting including the required Arial font in the enclosed agreed-upon labeling text.
6. The original language “This Patient Information has been approved by the U.S. Food and Drug Administration. Issued: X/XXXX” was re-added back to the enclosed agreed-upon labeling text.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry [SPL Standard for Content of Labeling Technical Qs and As](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf), available at [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf)

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed container labeling that are identical to the enclosed container labeling and submitted on March 15, 2019, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry titled [Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (April 2018, Revision 5)](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf). For administrative purposes, designate this submission “Final Printed
Container Labeling for approved NDA 210649.” Approval of this submission by FDA is not required before the labeling is used.

MARKET PACKAGE

Please submit one market package of the drug product when it is available to the following address:

Monica Zeballos  
Food and Drug Administration  
Center for Drug Evaluation and Research  
White Oak Building 22, Room: 6330  
10903 New Hampshire Avenue  
Silver Spring, Maryland

*Use zip code 20903 if shipping via United States Postal Service (USPS).  
Use zip code 20993 if sending via any carrier other than USPS (e.g., UPS, DHL, FedEx).*

PROPRIETARY NAME

If you intend to have a proprietary name for this product, the name and its use in the labeling must conform to the specifications under 21 CFR 201.10 and 201.15. We recommend that you submit a request for a proposed proprietary name review. (See the guidance for industry titled, “Contents of a Complete Submission for the Evaluation of Proprietary Names”, at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075068.pdf and “PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2018 through 2022”.)

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

The PREA requirement for this application was determined to be inapplicable.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the Prescribing Information, Medication Guide, and Patient Package Insert (as applicable) to:
OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Monica Zeballos, Pharm.D., Program Coordinator, at (301) 796-0840.

Sincerely yours,

{See appended electronic signature page}

Jeffrey Murray, M.D., M.P.H.  
Deputy Director  
Division of Antiviral Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling  
Prescribing Information  
Patient Package Insert  
Container Labeling
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JEFFREY S MURRAY
03/15/2019 04:29:44 PM